Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects

Abstract

Congenital cytomegalovirus (CMV) infection is the most common congenital infection in the world with approximately 0.5–2% of all live born infants, and can cause early or late severe neurological and neurisensorial damage. Although no drug has been licensed for therapy of congenital CMV infection, ganciclovir (GCV) and its oral pro-drug, valganciclovir (val-GCV), is increasingly being administrated to symptomatic infants, to improve neurodevelopmental and auditory outcome. Other potentially efficacious for therapy of congenital CMV disease are foscarnet and cidofovir, which have only been administered in few cases. A literature search was performed to look for evidence based or scientific articles evaluating pharmacokinetics, efficacy, and side effects of GCV/val-GCVand the other two anti-viral drugs.

• Anti-viral therapy
• cidofovir
• congenital cytomegalovirus infection
• foscarnet
• ganciclovir
• valganciclovir

Declaration of interest

The authors declare that they have no competing interests.